i don't know why you like the partnering prospect, giving away the rights (value) of the company where only a small sales force would be required to realize iplex's potential. insm accomplished the hardest part getting the drug approved and through the orphan group, why give the rights away now? data from other indications right now are more important than a partnering deal. as for trca trading at $7, the street is giving it credit for $60 million in cash it has which with low shares outstading accounts for $2/share.
Market Data 
Markets 
AI
